Pro-905, a Novel Purine Antimetabolite, Combines with Glutamine Amidotransferase Inhibition to Suppress Growth of Malignant Peripheral Nerve Sheath Tumor

0576214 - ÚOCHB 2024 RIV US eng J - Journal Article
Lemberg, K. M. - Ali, E. S. - Krečmerová, Marcela - Aguilar, J. M. H. - Alt, J. - Peters, D. E. - Zhao, L. - Wu, Y. - Nuha, N. - Asara, J. M. - Staedtke, V. - Pratilas, C. A. - Majer, Pavel - Rais, R. - Ben-Sahra, I. - Slusher, B. S.
Pro-905, a Novel Purine Antimetabolite, Combines with Glutamine Amidotransferase Inhibition to Suppress Growth of Malignant Peripheral Nerve Sheath Tumor.
Molecular Cancer Therapeutics. Roč. 22, č. 12 (2023), s. 1390-1403. ISSN 1535-7163. E-ISSN 1538-8514
R&D Projects: GA MŠMT(CZ) LM2023053
Institutional support: RVO:61388963
Keywords : loading 6-mercaptopurine therapies * standard dose 6-mercaptopurine * combination 6-mercaptopurine
OECD category: Medicinal chemistry
Impact factor: 5.7, year: 2022
Method of publishing: Open access
https://doi.org/10.1158/1535-7163.MCT-23-0258

Malignant peripheral nerve sheath tumors (MPNST) are highly aggressive soft-tissue sarcomas that arise from neural tissues and carry a poor prognosis. Previously, we found that the glutamine amidotransferase inhibitor JHU395 partially impeded tumor growth in preclinical models of MPNST. JHU395 inhibits de novo purine synthesis in human MPNST cells and murine tumors with partial decreases in purine monophosphates. On the basis of prior studies showing enhanced efficacy when glutamine amidotransferase inhibition was combined with the antimetabolite 6-mercaptopurine (6-MP), we hypothesized that such a combination would be efficacious in MPNST. Given the known toxicity associated with 6-MP, we set out to develop a more efficient and well-tolerated drug that targets the purine salvage pathway. Here, we report the discovery of Pro-905, a phosphoramidate protide that delivered the active nucleotide antimetabolite thioguanosine monophosphate (TGMP) to tumors over 2.5 times better than equimolar 6-MP. Pro-905 effectively prevented the incorporation of purine salvage substrates into nucleic acids and inhibited colony formation of human MPNST cells in a dose-dependent manner. In addition, Pro-905 inhibited MPNST growth and was well-tolerated in both human patient-derived xenograft (PDX) and murine flank MPNST models. When combined with JHU395, Pro-905 enhanced the colony formation inhibitory potency of JHU395 in human MPNST cells and augmented the antitumor efficacy of JHU395 in mice. In summary, the dual inhibition of the de novo and purine salvage pathways in preclinical models may safely be used to enhance therapeutic efficacy against MPNST.
Permanent Link: https://hdl.handle.net/11104/0345801